Basilea Pharmaceutica Ltd has announced that sales of its antifungal drug Cresemba (isavuconazole) by its licensing partner Pfizer in Europe have surpassed the milestone threshold, triggering a $25 million payment to Basilea.
The licensing agreement between Basilea and Pfizer for Cresemba encompasses Europe (excluding the Nordic countries) alongside 16 countries within the Asia Pacific region and China.
Recent market data reveals that the total global in-market sales of Cresemba reached $489 million for the 12 months spanning April 2023 to March 2024, reflecting a 24 percent increase compared to the previous year.
Isavuconazole, marketed under the name Cresemba, is available in both intravenous and oral forms. Basilea has established several licensing and distribution agreements for isavuconazole, covering approximately 115 countries. In the 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, isavuconazole is approved for use in patients from the age of 1 year and older for treating invasive aspergillosis and as an alternative treatment for mucormycosis when amphotericin B is unsuitable.
Isavuconazole also holds approvals in the United States and numerous other countries, including the U.K., China, and Japan. It carries orphan drug designation in the US, Europe, and Australia for its approved treatments.
